Bupropion is not licensed as an antidepressant in the UK, limiting its use. We highlight bupropion's distinct pharmacological profile and its potential benefits in treatment-resistant depression and people experiencing selective serotonin reuptake inhibitor-induced sexual dysfunction. The National Health Service repurposing medicines programme could improve equity of access for UK patients.
Journal article
2025-12-01T00:00:00+00:00
227
833 - 835
2
Bupropion, depression, inflammation, licensing, sexual dysfunction, Humans, Bupropion, United Kingdom, Depressive Disorder, Treatment-Resistant, Antidepressive Agents, Second-Generation, Selective Serotonin Reuptake Inhibitors, Drug Repositioning, Sexual Dysfunction, Physiological